Emcure Pharmaceuticals Ltd. has announced a significant price reduction for its weight management drug Poviztra® (semaglutide injection), cutting the starting dose price by 55% to improve patient access across India.
The revised pricing brings the 0.25 mg dose to Rs. 3,999 per month, down from Rs. 8,790. Prices across all strengths have been reduced by an average of 47%, with the new rates effective from April 3, 2026.
Poviztra® is available in five strengths ranging from 0.25 mg to 2.4 mg and is administered through a once-weekly pen device designed for ease and precision.
As the first Indian company to exclusively distribute and commercialise Poviztra®, a second brand of Novo Nordisk’s semaglutide injection, Emcure aims to expand access to a globally established obesity treatment.
Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, “The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity.3 Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale.”